1. Home
  2. CSTL vs RMT Comparison

CSTL vs RMT Comparison

Compare CSTL & RMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSTL
  • RMT
  • Stock Information
  • Founded
  • CSTL 2007
  • RMT 1993
  • Country
  • CSTL United States
  • RMT United States
  • Employees
  • CSTL N/A
  • RMT N/A
  • Industry
  • CSTL Medical Specialities
  • RMT Investment Managers
  • Sector
  • CSTL Health Care
  • RMT Finance
  • Exchange
  • CSTL Nasdaq
  • RMT Nasdaq
  • Market Cap
  • CSTL 471.5M
  • RMT 460.2M
  • IPO Year
  • CSTL 2019
  • RMT N/A
  • Fundamental
  • Price
  • CSTL $19.36
  • RMT $9.45
  • Analyst Decision
  • CSTL Strong Buy
  • RMT
  • Analyst Count
  • CSTL 6
  • RMT 0
  • Target Price
  • CSTL $37.67
  • RMT N/A
  • AVG Volume (30 Days)
  • CSTL 554.7K
  • RMT 111.5K
  • Earning Date
  • CSTL 08-04-2025
  • RMT 01-01-0001
  • Dividend Yield
  • CSTL N/A
  • RMT 7.37%
  • EPS Growth
  • CSTL N/A
  • RMT N/A
  • EPS
  • CSTL N/A
  • RMT 1.49
  • Revenue
  • CSTL $346,269,000.00
  • RMT N/A
  • Revenue This Year
  • CSTL N/A
  • RMT N/A
  • Revenue Next Year
  • CSTL $1.62
  • RMT N/A
  • P/E Ratio
  • CSTL N/A
  • RMT $6.18
  • Revenue Growth
  • CSTL 20.40
  • RMT N/A
  • 52 Week Low
  • CSTL $14.59
  • RMT $7.67
  • 52 Week High
  • CSTL $35.84
  • RMT $9.51
  • Technical
  • Relative Strength Index (RSI)
  • CSTL 58.66
  • RMT 50.97
  • Support Level
  • CSTL $18.81
  • RMT $9.39
  • Resistance Level
  • CSTL $21.33
  • RMT $9.55
  • Average True Range (ATR)
  • CSTL 0.92
  • RMT 0.17
  • MACD
  • CSTL 0.45
  • RMT -0.04
  • Stochastic Oscillator
  • CSTL 70.74
  • RMT 53.39

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

About RMT Royce Micro-Cap Trust Inc.

Royce Micro-Cap Trust Inc is a diversified closed-end investment company. The company is engaged in investing in micro-cap securities. It invests in the consumer discretionary sector including auto components, automobiles, diversified consumer services, hotels, restaurants and leisure, household durables, internet and catalog retail, leisure products, media, multiline retail, textiles, apparels, and luxury goods, Consumer staples sector including beverages, food, and staples retailing, food products, and personal products, Energy sector including energy equipment and services, and oil, gas, and consumable fuels. The company also invests in other sectors including healthcare, financials, industrials, IT, telecommunications, and materials.

Share on Social Networks: